UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September, 2020
Commission File Number: 001-38452
MEREO BIOPHARMA GROUP PLC
(Translation of registrants name into English)
4th Floor, One Cavendish Place,
London, W1G 0QF, United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Exhibit Index
Exhibits |
||
99.1 | Press release issued by Mereo BioPharma Group plc Result of General Meeting dated September 28, 2020. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: September 28, 2020
MEREO BIOPHARMA GROUP PLC | ||
By: | /s/ Charles Sermon | |
Name: Charles Sermon | ||
Title: General Counsel |
Exhibit 99.1
Mereo BioPharma Group plc
(Mereo or the Company or the Group)
Result of General Meeting
London and Redwood City, Calif., September 28, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), Mereo or the Company, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announces that all five resolutions (the Resolutions) proposed at the Companys General Meeting (General Meeting), held earlier today, were duly passed. The Board is pleased that all the resolutions received strong support from shareholders. Full details of the resolutions can be viewed in the Notice of General Meeting on the Companys website at www.mereobiopharma.com
The results of the proxy voting in advance of the General Meeting are shown below. On the record date there were 338,713,962 ordinary shares of £0.003 each in issue, each carrying one vote per share.
Resolution | Votes For | Votes at Chairmans Discretion |
Votes Against |
Votes Withheld |
Total Votes Cast |
Result | ||||||
1 | 129,413,324 | 0 | 9,258,138 | 17,565 | 138,689,027 | Passed | ||||||
2 | 138,317,100 | 0 | 178,850 | 193,077 | 138,689,027 | Passed | ||||||
3 | 138,558,837 | 0 | 92,945 | 37,245 | 138,689,027 | Passed | ||||||
4 | 125,187,297 | 0 | 13,290,680 | 211,050 | 138,689,027 | Passed | ||||||
5 | 124,695,799 | 0 | 13,216,200 | 777,028 | 138,689,027 | Passed |
About Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Mereos lead oncology product candidate, etigilimab (Anti-TIGIT), has completed a Phase 1a dose escalation clinical trial in patients with advanced solid tumors and has been evaluated in a Phase 1b study in combination with nivolumab in select tumor types. Mereos rare disease product portfolio consists of setrusumab, which has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta (OI), as well as alvelestat, which is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency (AATD) and in a Phase 1b/2 clinical trial in COVID-19 respiratory disease.
Mereo BioPharma Contacts:
Mereo |
+44 (0)333 023 7300 | |
Denise Scots-Knight, Chief Executive Officer |
||
N+1 Singer (Nominated Adviser and Broker to Mereo) |
+44 (0)20 7496 3081 | |
Phil Davies |
||
Will Goode |
Burns McClellan (US Investor Relations Adviser to Mereo) |
+01 212 213 0006 | |
Lisa Burns |
||
Steve Klass |
||
FTI Consulting (UK Public Relations Adviser to Mereo) |
+44 (0)20 3727 1000 | |
Simon Conway |
||
Ciara Martin |
||
Investors |
investors@mereobiopharma.com |